Skip to main content

Table 1 Comparison of clinical features between MDS patients with and without DNMT3A mutation

From: Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome

Variables

Total

DNMT3A mutated

DNMT3A wild

P value

(n = 469)

(n = 37, 7.9%)

(n = 432, 92.1%)

Gender†

   

0.201

 Male

315 (67.2)

21 (6.7)

294 (93.3)

 

 Female

154 (32.8)

16 (10.4)

138 (89.6)

 

Age (year)#

65.5 (16~98)

69.6 (35~89)

65.5 (16~98)

0.151

Lab data#

 WBC (× 109/L)

3.84 (0.44~355.3)

5.02 (0.49~59.83)

3.73 (0.44~355.3)

0.942

 Hb (g/dL)

8.3 (3~15)

8.1 (5~11)

8.3 (3~15)

0.555

 Platelet (× 109/L)

74 (2~931)

162 (14~460)

74 (2~931)

0.045

 LDH (mckat/L)

8.133 (2.422~113.677)

8.208 (3.507~24.733)

8.133 (2.422~113.677)

0.739

FAB subtype††

   

0.002

 RA

171 (36.5)

4 (2.3)

167 (97.7)

0.001

 RARS

32 (6.8)

6 (18.8)

26 (81.2)

0.031

 RAEB

159 (33.9)

18 (11.3)

141 (88.7)

0.069

 RAEB-T

53 (11.3)

5 (9.4)

48 (90.6)

0.593

 CMML

54 (11.5)

4 (7.4)

50 (92.6)

> 0.999

2016 WHO classification ††

(n = 362)

(n = 28, 7.7%)

(n = 334, 92.3%)

0.011

 MDS-SLD

60 (16.6)

1 (1.7)

59 (98.3)

0.062

 MDS-MLD

106 (29.3)

3 (2.8)

103 (97.2)

0.029

 MDS-RS-SLD

18 (5.0)

3 (16.7)

15 (83.3)

0.154

 MDS-RS-MLD

13 (3.6)

3 (23.1)

10 (76.9)

0.070

 MDS with isolated del(5q)

2 (0.6)

0 (0.0)

2 (100.0)

> 0.999

 MDS-EB-1

78 (21.5)

8 (10.3)

70 (89.7)

0.343

 MDS-EB-2

81 (22.4)

10 (12.3)

71 (87.7)

0.097

 MDS-U

4 (1.1)

0 (0.0)

4 (100.0)

> 0.999

Karyotype risk†† Φ

(n = 437)

(n = 35)

(n = 402)

0.883

 Good

263 (60.2)

20 (7.6)

243 (92.4)

0.721

 Intermediate

88 (20.1)

7 (8.0)

81 (92.0)

> 0.999

 Poor

86 (19.7)

8 (9.3)

78 (90.7)

0.658

IPSS†† §

(n = 437)

(n = 35)

(n = 402)

0.372

 Low

68 (15.6)

4 (5.9)

64 (94.1)

0.630

 INT-1

181 (41.4)

11 (6.0)

170 (94.0)

0.283

 INT-2

107 (24.5)

11 (10.3)

96 (89.7)

0.412

 High

81 (18.5)

9 (11.1)

72 (88.9)

0.259

IPSS-R††ζ

(n = 437)

(n = 35)

(n = 402)

0.692

 Very low

13 (3.0)

1 (7.7)

12 (99.3)

> 0.999

 Low

104 (23.8)

7 (6.7)

97 (93.3)

0.682

 Intermediate

106 (24.2)

6 (5.7)

100 (94.3)

0.411

 High

113 (25.9)

10 (8.8)

103 (91.2)

0.841

 Very high

101 (23.1)

11 (10.9)

90 (89.1)

0.294

  1. Abbreviations: FAB, French-American-British classification; RA, refractory anemia; RARS, refractory anemia with ring sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-T, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; MDS-SLD, MDS with single lineage dysplasia; MDS-MLD, MDS with multilineage dysplasia; MDS-RS-SLD, MDS with ring sideroblasts with single lineage dysplasia; MDS-RS-MLD, MDS with ring sideroblasts with multilineage dysplasia; MDS-EB1 , MDS with excess blasts-1; MDS-EB2, MDS with excess blasts-2; MDS-U, MDS, unclassified
  2. †Number of patients (% among the males or females)
  3. #Median (range)
  4. ††Number of patients (% among patients of each subgroup)
  5. ΦGood: normal karyotype, isolated -Y, del(5q), or del(20q); Poor: complex (≧ 3 abnormalities) or chromosome 7 anomalies; Intermediate, other abnormalities
  6. § IPSS (international prognosis scoring system): low, 0; intermediate (INT)-1, 0.5–1; INT-2, 1.5–2; and high, ≥ 2.5
  7. ζ IPSS-R (revised international prognostic scoring system): very low, ≦1.5; low, > 1.5–3; intermediate, > 3–4.5; high, > 4.5–6; and very high, > 6
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us